Clinical utility of asthma biomarkers: from bench to bedside

Susanne JH Vijverberg1,2,*  
Bart Hilvering2,*  
Jan AM Raaijmakers1  
Jan-Willem J Lammers2  
Anke-Hilse Maitland-van der Zee1,*  
Leo Koenderman2,*

1Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands;  
2Department of Respiratory Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands  
*These authors contributed equally to this work

Abstract: Asthma is a chronic disease characterized by airway inflammation, bronchial hyperresponsiveness, and recurrent episodes of reversible airway obstruction. The disease is very heterogeneous in onset, course, and response to treatment, and seems to encompass a broad collection of heterogeneous disease subtypes with different underlying pathophysiological mechanisms. There is a strong need for easily interpreted clinical biomarkers to assess the nature and severity of the disease. Currently available biomarkers for clinical practice – for example markers in bronchial lavage, bronchial biopsies, sputum, or fraction of exhaled nitric oxide (FeNO) – are limited due to invasiveness or lack of specificity. The assessment of markers in peripheral blood might be a good alternative to study airway inflammation more specifically, compared to FeNO, and in a less invasive manner, compared to bronchoalveolar lavage, biopsies, or sputum induction. In addition, promising novel biomarkers are discovered in the field of breath metabolomics (eg, volatile organic compounds) and (pharmaco)genomics. Biomarker research in asthma is increasingly shifting from the assessment of the value of single biomarkers to multidimensional approaches in which the clinical value of a combination of various markers is studied. This could eventually lead to the development of a clinically applicable algorithm composed of various markers and clinical features to phenotype asthma and improve diagnosis and asthma management.

Keywords: asthma, airway inflammation, biological markers, pharmacogenomics, metabolomics

Introduction to the pathophysiology of asthma

Asthma affects over 300 million individuals worldwide,¹ making it one of the most prevalent common chronic diseases. Although the respiratory disease is rarely fatal, the economic burden is extensive due to direct and indirect medical expenses, including prescription drug costs, health care costs, and productivity losses.²

The disease is characterized by airway inflammation, bronchial hyperresponsiveness, and recurrent episodes of reversible airway obstruction. Asthma can be classified as “atopic” or “nonatopic” based on the presence (atopic) or absence (nonatopic) of specific immunoglobulin (IgE) antibodies to common environmental allergens. Atopic asthma is the most common form of asthma. In allergen-sensitized patients with atopic asthma, re-exposure to an aeroallergen will lead to an IgE-mediated inflammatory cascade in the airways. Airway resident cells (ie, macrophages and mast cells), newly mobilized immune cells (ie, eosinophils and neutrophils), and epithelial cells play an important role in this inflammatory cascade.³ In allergic inflammation, there seems to be a disturbed balance in T helper (Th)1-type and Th2-type cytokines – with dominance...
towards Th2 cytokines. Th2 cells produce cytokines such as interleukin (IL)-4 and IL-13, which induce a class-switch in B-cells to the production of IgE. Th2 cells also produce IL-5, which recruits eosinophils to the lung, and IL-9, which stimulates mast cell proliferation. Upon activation, mast cells start to produce histamine, cysteinyl-leukotrienes, and prostaglandin D2, which in its turn will lead to the additional recruitment of eosinophils, Th2 cells, and basophils to the tissue.

Parallel to the allergic asthma model with airway epithelial cells and the adaptive immune response as important pillars, an additional nonallergic asthma paradigm has been proposed. In the nonallergic asthma model, the innate immune system responds to constantly invading respiratory viruses and bacteria. This systemic innate response is driven by sentinel cells such as macrophages, dendritic cells, granulocytes, and innate lymphoid cells. A recent review by Holtzman provides a comprehensive overview of both the allergic and nonallergic immune response in asthma.

A prolonged presence of activated inflammatory cells in the airways leads to chronic inflammation and induces tissue alterations in composition, content, and organization of the airways (“airway remodeling”). Important cytokines released by epithelial cells and associated with remodeling are IL-25, thymic stromal lymphopoietin, and IL-33. The remodeling response is characterized by subepithelial basement membrane thickening, epithelial cell disruption, neoangiogenesis, goblet cell metaplasia, enlarged submucosal glands, and airway smooth muscle hyperplasia. This airway remodeling is regarded as a continuous process, while the number of inflammatory cells infiltrated in the respiratory tract can vary over time. This latter process is evoked by stimuli such as allergens, climate, or respiratory tract infections. However, the observation of airway remodeling in young asthma patients suggests that the process may even precede airway inflammation.

**Asthma biomarkers for diagnosis, phenotyping, and treatment efficacy**

Asthma diagnosis and management is generally based on reported asthma symptoms, often combined with lung function tests to assess reversible airway obstruction and airway hyperresponsiveness. However, symptoms and lung function measurements may not reflect underlying airway inflammation. Bronchoscopy with biopsies and bronchoalveolar lavage (BAL) are considered the gold standard to assess airway inflammation, but are too invasive for general application in clinical practice. In addition, asthma seems to encompass a broad collection of heterogeneous disease subtypes with different underlying pathophysiological mechanisms. There is a need for asthma biomarkers to identify clinical relevant asthma phenotypes, optimize diagnosis, and guide treatment. In this paper, we will provide an overview of asthma biomarkers already available for clinical practice and promising biomarkers currently under development (Figure 1). In addition, we will address the promises and barriers of the implementation of asthma biomarkers into clinical practice.

**Clinically available biomarkers**

**Sputum induction, bronchoscopy/biopsy, and bronchoalveolar lavage**

Tissue-specific diagnostic methods such as bronchoalveolar lavage, bronchoscopy, or bronchial biopsy, are used to measure airway inflammation and remodeling, and provide reliable and detailed clinical information of asthmatic patients. Airway remodeling has been observed in bronchial biopsies of both adults and children with asthma. BAL fluid of asthmatic patients shows elevated levels of Th2 cytokines compared to healthy individuals. In difficult-to-treat asthma in children, BAL and endobronchial biopsy should be considered to objectify the presence of airway eosinophilia and other typical pathological features of asthma. Thus, invasive and tissue-specific diagnostic methods are valuable in certain patient populations and clinical research settings. However, the invasiveness of these diagnostic procedures limits the use of these methods for daily clinical routine in most asthma patients. Even sputum induction, a diagnostic technique in which the patient inhales nebulized saline solution in increasing concentrations to liquefy sputum, is regarded as too invasive, technically complex, and too variable for daily clinical routine. This allocates the procedure to specialized medical centers. There is a strong correlation between cellular components present in airway fluid obtained by BAL and cells present in airway fluid obtained by sputum induction. Therefore, compared to BAL, sputum induction is the preferred method to diagnose the inflammatory phenotype of asthma classically based on the presence of different types of granulocytes. Recent studies indicate that the performance of this technique increases when combined with the analysis of other cellular components such as exosomes and signaling proteins.

Distinct inflammatory patterns have been established in the sputum of asthmatic adults and asthmatic children based on eosinophil and neutrophil percentages of total nonsquamous cells in the sputum. Currently, four inflammatory phenotypes have been identified based on
analysis of sputum: eosinophilic; neutrophilic; mixed; and paucigranulocytic types (Figure 2). It has been suggested that higher levels of sputum eosinophils are associated with a better response to corticosteroids, but results remain inconsistent. Furthermore, the pattern of inflammatory sputum phenotypes seems to be different for adult patients and pediatric patients, and the reproducibility of sputum induction measurements over time has been a point of scientific debate since the introduction of this technique.

Other sputum and BAL markers that have been investigated include soluble mediators such as eosinophil cationic protein (ECP), hypoxia inducible factor-1α (HIF-1α), and vascular endothelial growth factor (VEGF). ECP is released during degranulation of eosinophils and can be measured in sputum, BAL fluid, and in serum. It is considered to be a nonspecific marker for inflammation and therefore lacks the specificity for diagnosing asthma. Meijer et al showed that sputum ECP has no predictive value for clinical response to corticosteroids in asthmatic patients. Its added value as a diagnostic tool would be in the measurement of the extent of inflammation and severity of asthma; eg, moderate versus severe asthma.

HIF-1α and VEGF protein levels have shown to be upregulated in lung specimens from allergen-challenged asthma patients obtained by BAL and endobronchial biopsies.

**Nitric oxide in exhaled breath**

Almost a decade ago, the first reports emerged of increased levels of nitric oxide in exhaled breath (FeNO) in patients...
Nitric oxide is produced when the amino acid L-arginine is catalyzed by nitric oxide synthases (NOS) into the amino acid L-citrulline. There are three known isoforms of NOS, but in particular, inducible NOS seems to play a role in the elevated levels of NO in the exhaled breath of asthmatics. The expression of the enzyme is upregulated by a wide range of inflammatory cytokines. It remains unclear which cells are responsible for the increased NO production, but airway epithelial cells and eosinophils are thought to be the most important candidates. It is thought that inflamed airways will produce increased levels of NO. High FeNO is thought to be a surrogate marker of ongoing eosinophilic airway inflammation, and may reflect uncontrolled asthma and predict asthma exacerbations.

Despite the initial enthusiasm about FeNO as a new and noninvasive marker of airway inflammation, the clinical usefulness of FeNO to measure asthma control is still debated. Studies that have investigated the association between asthma control and FeNO provide inconsistent results (Table 1), and studies assessing the relationship between FeNO and other airway inflammation markers, such as sputum eosinophilia or the presence of eosinophils in bronchial specimens, remain inconclusive.37,38 This may be partly caused by a non-overlap in asthma symptoms and airway inflammation. Furthermore, this relationship is complicated due to various other factors that seem to influence FeNO levels, including age, atopy, medication use, therapy adherence, and airway infections.38 In addition, tailoring asthma treatment based on FeNO measurements did not decrease asthma exacerbations or lead to better asthma control according to a meta-analysis performed by Petsky et al.39 FeNO might, nevertheless, still be a valuable marker in asthma management. Zacharasiewicz et al showed that the combination of increased levels of FeNO and the percentage of sputum eosinophils were significant predictors of exacerbation upon steroid reduction in children with stable asthma.40 Studies by Szefler et al41 and Knuffman et al42 showed that pediatric asthma patients with elevated FeNO levels were more likely to respond to corticosteroids compared to montelukast.

Reports on the relationship between FeNO and treatment response remain inconsistent, though there is a suggestion that higher baseline FeNO is associated with a better response to treatment.43 Although the clinical value of a single FeNO measurement is limited, combining this measure with other markers of airway inflammation may lead to a more accurate assessment of underlying disease state.

**Biomarkers under development**

**Blood**

Peripheral blood is easy to obtain, and the procedure itself is less invasive than sputum induction and bronchoscopy. Since inflamed tissue releases chemoattractants and cytokines, which recruit activated immune cells from the peripheral blood, the dynamic process of immune cells entering and leaving the blood stream can be used as an indirect readout of the state of disease.

Peripheral blood eosinophilia has been described extensively as a potential asthma biomarker.44 Blood eosinophilia correlates with bronchial hyperresponsiveness and asthma-related inflammation.45 The specificity of using peripheral blood eosinophilia to diagnose asthma is, however, rather low, as allergies, autoimmune disease, and parasitic infections cause blood eosinophilia as well. Therefore, its role as a diagnostic measurement remains limited. The same applies to total and allergen-specific IgE levels in serum.46 Several studies have evaluated whether the presence of inflammatory soluble mediators such as chemokines and
Table 1 Studies that assessed the association between fraction of FeNO and asthma control

<table>
<thead>
<tr>
<th>Study population</th>
<th>Study design</th>
<th>NO device</th>
<th>Asthma control</th>
<th>Outcome</th>
<th>Evidence for association</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijverberg et al</td>
<td>Cross-sectional</td>
<td>NIOX Mino</td>
<td>ACQ-6</td>
<td>Weak positive correlation between FeNO and ACQ score ($R_s = 0.13$, $P = 0.002$), but poor accuracy to discriminate poor from well-controlled asthma (AUC: 0.56, 95% CI: 0.52–0.61, $P = 0.008$).</td>
<td>+/-</td>
</tr>
<tr>
<td>Ozier et al</td>
<td>Prospective follow-up of 3 wks for controlled patients and 3–6 months for uncontrolled patients</td>
<td>EndoNO, NIOX Mino</td>
<td>ACQ-6</td>
<td>No correlation between FeNO measurements and ACQ scores. PPV of FeNO &lt; 50% to predict uncontrolled asthma. FeNO had a high NPV to predict loss of control in already controlled patients (&gt;95%).</td>
<td>+/-</td>
</tr>
<tr>
<td>Mahut et al</td>
<td>Prospective, 12 weeks of follow-up</td>
<td>ENDONO, 8000</td>
<td>7-item and 6-item ACQ</td>
<td>FeNO did not correlate with ACQ at inclusion or during follow-up.</td>
<td>-</td>
</tr>
<tr>
<td>Sardón-Prado et al</td>
<td>Cross-sectional</td>
<td>NIOX Mino</td>
<td>CAN questionnaire</td>
<td>Weak correlation between FeNO and asthma control ($r = 0.2$).</td>
<td>+/-</td>
</tr>
<tr>
<td>Pérez-de-Llano et al</td>
<td>Prospective</td>
<td>NIOX Mino</td>
<td>ACT</td>
<td>FeNO had a PPV of 87.5% and a NPV of 90.6% to predict asthma control.</td>
<td>+</td>
</tr>
<tr>
<td>Shirai et al</td>
<td>Cross-sectional</td>
<td>Sievers NOA 280i</td>
<td>ACT</td>
<td>Weak correlation between FeNO and asthma control ($r = -0.31$, $P = 0.003$).</td>
<td>+/-</td>
</tr>
<tr>
<td>Khalili et al</td>
<td>Cross-sectional</td>
<td>NIOX</td>
<td>ACT, ACQ, NAEPP goals of therapy, JTFPP on attaining optimal asthma control, GINA guidelines</td>
<td>No significant association was found between FeNO level and asthma control based on ACQ ($P &gt; 0.99$), ACT ($P = 0.53$), NAEPP ($P = 0.53$), JTFPP ($P = 0.30$), or GINA ($P = 0.86$) criteria.</td>
<td>-</td>
</tr>
<tr>
<td>Michils et al</td>
<td>Prospective with post hoc data analysis</td>
<td>LR 2000</td>
<td>ACQ-6</td>
<td>FeNO is a good marker of asthma control over time (especially in patients with low doses of ICS). FeNO decrease &lt;40% or increase &lt;30% precludes asthma control optimization or deterioration, (NPV: 79% and 82%, respectively). In the low-dose ICS group, a decrease &gt;40% indicated control optimization (PPV: 83%).</td>
<td>+</td>
</tr>
<tr>
<td>Senna et al</td>
<td>Cross-sectional</td>
<td>CLD 88 sp</td>
<td>ACT</td>
<td>Good correlation between ACT score and FeNO ($r = 0.7$, $P = 0.001$). FeNO was associated with poor asthma control, but the association was strongest when FeNO was combined with markers in exhaled breath condensate (AUC 0.761, $P &lt; 0.001$).</td>
<td>+/-</td>
</tr>
<tr>
<td>Robroeks et al</td>
<td>Cross-sectional</td>
<td>NIOX</td>
<td>Based on GINA</td>
<td>No significant correlation between FeNO and ACQ ($r = 0.48$, $P = 0.06$).</td>
<td>-</td>
</tr>
<tr>
<td>Rosias et al</td>
<td>Cross-sectional</td>
<td>NIOX</td>
<td>ACQ</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Study population</th>
<th>Study design</th>
<th>NO device</th>
<th>Asthma control</th>
<th>Outcome</th>
<th>Evidence for association</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strunk et al&lt;sup&gt;11&lt;/sup&gt;</td>
<td>144 children with mild to moderate persistent asthma (age: 6–17 yrs)</td>
<td>Cross-over RCT ICS/LTRA</td>
<td>NIOX</td>
<td>Patient diary</td>
<td>No correlation between FeNO and clinical characteristics.</td>
</tr>
<tr>
<td>Franklin et al&lt;sup&gt;13&lt;/sup&gt;</td>
<td>155 children (mean age: 11.5 ± 2.3 yrs)</td>
<td>Prospective birth cohort</td>
<td>Severs</td>
<td>Modified ATS questionnaire</td>
<td>FeNO was not associated with symptoms (recent wheeze), P = 0.53.</td>
</tr>
<tr>
<td>Jones et al&lt;sup&gt;14&lt;/sup&gt;</td>
<td>78 mild/moderate asthma patients (age: 18–74 yrs)</td>
<td>Prospective, max 6 weeks or to LOC</td>
<td>Unknown</td>
<td>LOC based on: lung function decrease, increase bronchodilator use, nocturnal asthma symptoms, distressing asthma symptoms</td>
<td>Good correlation between FeNO at final study visit, change of FeNO over time and symptom score (r = 0.33, P = 0.004, r = 0.45, P = 0.0001, respectively). Single FeNO measurements and changes of FeNO had PPV that ranged from 80% to 90% for predicting and diagnosing LOC. FeNO significantly correlated with asthma symptoms within the past 2 weeks (P = 0.02), dyspnea score (P = 0.02) and daily use of rescue medications (P = 0.01).</td>
</tr>
<tr>
<td>Sippel et al&lt;sup&gt;15&lt;/sup&gt;</td>
<td>100 asthma patients (age: 7–80 yrs)</td>
<td>Cross-sectional</td>
<td>Severs</td>
<td>National Heart, Blood and Lung Institute Epidemiology Standardization project/ dyspnea score</td>
<td>–</td>
</tr>
</tbody>
</table>

Abbreviations: ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; ATS, American Thoracic Society; AUC, area under the receiver operating characteristic curve; CAN, Control de Asma en Ninos; FeNO, fraction of exhaled nitric oxide; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroids; JTFPP, Joint Task Force Practice Parameter; LTRA, leukotriene receptor antagonist; NAEPP, National Asthma Education and Prevention Program; LOC, loss of asthma control; NPV, negative predictive value; PPV, positive predictive value; RCT, randomized controlled trial; wks, weeks; yrs, years; CI, confidence interval.
of antibodies recognizing activated FcγRs.51,59 These data demonstrated that eosinophils become first activated in the peripheral blood and subsequently home for the tissue, leaving behind unprimed cells.60 These studies have indicated that changes in the phenotype of inflammatory cells can aid in the diagnosis of the type and extent of severity of allergic asthma. But they also show that the differences are very subtle and not applicable yet in the clinical routine.

Closer to clinical implementation might be the biomarker periostin. Periostin is a recently discovered matricellular protein that is secreted by bronchial epithelial cells under the influence of IL-13. The presence of periostin in serum correlates strongly with sputum eosinophilia.61 A study by Corren et al showed that patients with high levels of serum periostin responded better to lebrikizumab (anti-IL-13 therapy) compared to patients with low levels of periostin.62

Air

The measurement of volatile organic compounds (VOCs) in exhaled breath is a novel metabolomic approach to study molecular signatures of respiratory disease. Exhaled breath contains a complex mixture of potentially thousands of VOCs. These compounds are produced due to metabolic processes in the airways, and the presence and/or concentrations of the different compounds are likely influenced by the presence of airway inflammation. There exist different methods to assess VOCs; one can assess profiles of VOCs (“breathprints”) present in exhaled breath using polymer-based gas sensor arrays (“electronic nose”),63 or identify individual molecular components using gas chromatography-mass spectrometry (GC-MS).64 Asthma patients can be differentiated from healthy controls based on their breathprints,65 as can asthmatic patients from COPD patients.66 However, the method was less successful in distinguishing mild asthmatics from severe asthmatics.66 Breathprints of COPD patients do correlate with the presence of eosinophils and neutrophils in induced sputum, as well as with levels of ECP and myeloperoxidase in induced sputum, suggesting that the electronic nose might be capable of assessing distinct types of underlying airway inflammation.67

Using the other approach, GC-MS, Dallinga et al showed that the measurement of a limited set of VOCs in exhaled air could differentiate asthmatic children from controls with high sensitivity (95%) and high specificity (89%).64 A study by Ibrahim et al showed that a set of 15 VOCs could discriminate asthmatic patients from controls, and also could classify patients according to inflammatory sputum phenotype and asthma control (based on the Asthma Control Questionnaire).68

The assessment of VOC in exhaled breath seems to be a very promising approach, especially when knowledge of clinically relevant VOCs is integrated into a user-friendly handheld device such as an electronic nose. However, validation of clinical relevant VOC patterns in a large population of asthmatic patients is necessary, as well as longitudinal assessment of VOC patterns, the assessment of the influence of asthma treatment, and emergence of international guidelines on VOC measurement. A large Europe-wide study to assess the clinical utility of VOCs in asthma in-depth is currently taking place.69

Biomarkers in breath can also be measured in exhaled breath condensate (EBC). When exhaled breath is cooled, a liquid phase can be obtained, which contains condensed water vapor as well as nonvolatile substances. Various markers in EBC have been found to be elevated in asthmatics when compared to healthy individuals, including adenosine concentration,60 markers of oxidative stress (ie, hydrogen peroxide),71 cytokines and chemokines,72 nitric oxide-related products,73 isoprostanes,74 and leukotrienes.74 Furthermore, the pH of EBC has been reported to be decreased in acute asthmatics and poorly controlled asthmatics.75,76

In spite of these results, the measurement of markers in EBC is still in its research phase, and several important methodological problems complicate the clinical utility of EBC.77 A standardized methodology for EBC collection is lacking, as are established reference values. Various factors such as the type of condenser equipment used, cooling temperature, condenser tube coating, cleaning procedures, breathing patterns, ambient air pollution, or concentrations of relevant cytokines too low for reliable determination influence the measurement and compromise reproducibility.

Urine: leukotriene metabolites

Cysteinyl leukotrienes (LTs) C4 and D4 are lipid mediators, which are thought to play a role in asthma pathogenesis. They can be released from various cells, including eosinophils, neutrophils, and mast cells. LTC4 and LTD4 in the plasma are rapidly converted into the less active LTE4 metabolite. A fraction of LTE4 is excreted in urine. The urinary LTE4 (uLTE4) concentration is used as a marker of total body LT production.79 Studies by Szefler et al and Cai et al showed that asthmatic patients with higher levels of uLTE4 were more likely to respond to leukotriene antagonists (LTRA)
when compared to asthmatic patients with lower uLTE$_4$ levels.  

(Pharmacogenomics)

Twin studies have shown that asthma contains a considerable genetic component.  

Genome-wide association studies have identified several loci to be associated with asthma risk, including the ORMDL3 locus, ADAM33, and various cytokines and cytokine receptor genes (IL18R1, IL33, IL2RB, IL10, TGFB1, and IL6R).  

A recent review by Dijk et al provides a thorough overview of asthma susceptibility genes that have been found by genome-wide association studies.  

Nevertheless, effect sizes are small, and the identified genetic variants can only explain a small part of the asthma heritability. This could be due to the heterogeneity in asthma phenotypes and the underestimated influence of environmental–gene interactions.  

For example, recent work by Ierodiakonou et al showed an interaction between variation in TGFB1 and smoking on asthma severity.  

Carrying a G-allele of rs6957 in TGFB1 was associated with higher submucosal eosinophils and basement membrane thickness, but only in current or ex-smoking asthmatics.  

A more promising genetic approach for clinical asthma practice might be pharmacogenomics: the association of genomic variations and medication response. Variation in genes coding for proteins involved in the drug metabolism pathway may influence drug concentration and efficacy.  

Observational studies have found genetic variation to be associated with persistent symptoms as well as with lung function in steroid-treated asthmatics.  

A study by Hawkins et al found a positive correlation with variations in STIP1, coding for an adaptor protein in the glucocorticoid receptor complex, and baseline lung function and improvement in lung function upon corticosteroid treatment in 382 adults with asthma.  

A study by Tantisira et al showed that asthma patients with a variant in the GLCCI1 have less improvement in lung function upon inhaled corticosteroids (ICS) treatment.  

GLCCI1 encodes Glocorticoid Induced Transcript 1, a protein of unknown function. Furthermore, a single-nucleotide polymorphism in the FCER2 gene, coding for a low-affinity IgE receptor, has been associated with an increased risk of asthma-related hospital visits, uncontrolled asthma, and higher daily steroid dosages.  

Variation in TBX21 (encoding transcription factor T-bet) has been related to improved airway responsiveness in childhood asthma upon treatment with ICS. T-bet is thought to be an important regulator of the Th1/Th2 balance.  

Pharmacogenomic studies on response to LTRA have found most association with ALOX5, a 5-lipoxgenase, and LTC4S, a glutathione S-transferase. However, a step closer to clinical implementation is the assessment of the beta-adrenergic receptor gene (ADRB2) in order to determine response to β2-agonists, for which randomized clinical trial (RCT) data are available. The beta-adrenergic receptor is a G-protein coupled receptor that is expressed in smooth muscle in the airways; activation induces bronchial relaxation. β2-agonists are the most frequently prescribed drugs to relieve airway obstruction, and act through the beta-adrenergic receptor. Evidence suggests that genetic variations in the gene are associated with an altered treatment response.  

Recently, a small RCT based on prospective testing of genetic variation in the ADRB2 gene (alteration in amino acid at position 16; Arg16Gly) showed encouraging results in 62 children with persistent asthma. Asthmatic children homozygous for the variant genotype were randomized to a long-acting β2 agonist (LABA) plus ICS or to LTRA plus ICS. The group treated with ICS and LTRA scored better on asthma symptoms and quality of life, used less rescue medication, and were fewer days absent from school compared to the children treated with LABA plus ICS, suggesting that asthmatic children homozygous for ADRB2 Arg16Gly substitution (B16 Arg/Arg) benefit more from LTRA compared to LABA as add-on treatment to ICS. Yet there was no difference in lung function improvement.  

On the other hand, RCTs performed in adults found no effect. A post hoc pharmacogenetic analysis of two large RCTs in which asthmatic patients were treated with LABA only or LABA combined with ICS found no differences in exacerbations, use of rescue medication, night awakenings, and lung function when patients were stratified according to differences in ADRB2 Arg16Gly genotype. In a crossover RCT, asthmatic patients with the B16 Arg/Arg (homozygote for the risk allele) or B16 Gly/Gly (homozygote for the wild-type allele) were randomized to LABA plus ICS or placebo plus ICS. There was no difference in lung function improvement between the groups when ICS was added. Remarkably, airway responsiveness in the patients with B16 Gly/Gly did improve significantly when ICS was added to the treatment, while it did not in the B16 Arg/Arg group. Airway responsiveness was measured as methacholine PC$_{20}$ doubling dose: the dose of methacholine that provokes a 20% drop in the volume of exhaled air during the first second of a forced expiratory maneuver.  

So far, pharmacogenetic studies have been limited by small sample sizes, heterogeneous populations, and lack
of replication. However, the emergence of new sequencing technologies and innovative strategies of analyses, as well as the increase in international research consortia, may lead to the identification and replication of clinical relevant associations in the near future. In addition, the development of innovative – though expensive – targeted treatment strategies (such as omalizumab [anti-IgE], mepolizumab [anti-IL-5], and lebrikizumab [anti-IL-13]) may provide a novel clinical context for pharmacogenetics in order to identify subgroups of asthma patients that will benefit the most from these treatments.

Ease of biomarker detection and current limitations
Progressive insight into medical biology leads to a layered profile of studying disease mechanisms. Asthma research is shifting from a broad perspective (studying symptom expression, lung function, and response to medication) to a more narrow focus: cellular profiles, protein analysis, and genetic markers, possibly combined with clinical measures. These biological parameters can be measured in different body compartments, and build up to a complexity that has not yet been fully understood. From a biological point of view, there are an almost indefinite number of possible biomarkers that can be measured in the context of asthma. Yet the clinical applicability (eg, clinical added value, specificity, sensitivity, and invasiveness) limits the number of appropriate clinical usable biomarkers. Noninvasive, reliable, and easily interpreted biomarkers would ideally be standard in daily clinical routine, but are currently unavailable.

Conclusion and future directions
Single biomarker approaches to phenotype asthma are increasingly regarded to be inaccurate and outdated. In diagnosing the presence of eosinophilic inflammation for example, FeNO is a very sensitive biomarker, but not very specific. Intuitively, combining FeNO with markers of eosinophilic inflammation (such as the percentage of eosinophils in peripheral blood or eosinophil receptor expression) or other biomarkers would increase specificity. To test this hypothesis, studies combining multiple known biomarkers should be performed. Currently, research consortia like U-BIOPRED (Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes, http://www.ubiopred.european-lung-foundation.org/) and SARP (Severe Asthma Research Program, http://www.severeasthma.org/) aim to integrate the process of data collection and multidimensional approaches to phenotype asthma.

Single biomarker approaches remain important in the process of biomarker discovery, as newly identified biomarkers can be integrated in a multidimensional approach to strengthen the diagnostic ability of a clinically applicable algorithm to phenotype asthma. Only then will personalized asthma treatment be in reach.

Disclosure
Susanne JH Vijverberg has been paid by an unrestricted grant from GlaxoSmithKline (GSK). Bart Hilvering has no financial relationship with a commercial entity that has an interest in the subject of this manuscript. Jan AM Raaijmakers is a part-time professor at the Utrecht University, Vice-President External Scientific Collaborations for GSK in Europe, and holds stock in GSK. Anke-Hilse Maitland-van der Zee received an unrestricted grant from GSK. Furthermore, the department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, which employs authors Susanne JH Vijverberg, Jan AM Raaijmakers, and Anke-Hilse Maitland-van der Zee, has received unrestricted research funding from the Netherlands Organisation for Health Research and Development, the Dutch Health Care Insurance Board, the Royal Dutch Pharmacists Association, the private public-funded Top Institute Pharma, including co-funding from universities, government, the EU Innovative Medicines Initiative, EU 7th Framework Program, the Dutch Medicines Evaluation Board, the Dutch Ministry of Health, and industry (including GSK, Pfizer, and others). Jan-Willem Lammers and Leo Koenderman are full professors in the Department of Respiratory Medicine at the University Medical Centre Utrecht. Both collaborated in a TI-Pharma–funded project. TI-Pharma is a public private partnership between the Universities of Utrecht, Groningen, Maastricht, the Dutch government, GSK, Nycomed, and Danone.

References


